The CHO expression system offers significant potential in the animal health sector, driven by its strengths in secretory expression and complex post-translational modifications. However, its broader adoption has been limited by the industry’s stringent requirements for high expression yields and strong cost sensitivity.

Canton Biologics leverages a proprietary CHO expression platform, integrating optimized vectors and chemically defined media to significantly enhance productivity while reducing cost-of-goods (COGs). This enables the practical and scalable application of CHO-based systems in animal health.

We have established advanced antigen expression platforms targeting animal coronaviruses, herpesviruses, and flaviviruses, supporting customized antigen production for livestock and poultry subunit vaccines. In parallel, dedicated platforms for recombinant proteins, therapeutic monoclonal antibodies, and polyclonal antibodies have been developed to provide end-to-end solutions for innovative companion animal therapeutics.

In addition, our nanoparticle technology platform enables the assembly of defined multimeric structures, including trimers, tetramers, 24-mers, and 180-mers, offering flexible design options to address diverse vaccine and biologics development needs across the animal health sector.